8月21日晚间，莱美药业(300006)发布2025年半年报，公司实现营业收入3.77亿元，报告期内，公司持续 聚焦优势细分领域，巩固公司拳头产品卡纳琳在相关领域的优势领先地位；保持新品持续引进，加快对 已引入新品的上市转换；通过加快高质量仿创新产品研发和技术引进，扩增仿制药业务；加大自主创新 力度，推动公司健康持续发展。 （文章来源：证券时报网） 报告显示，公司构建短、中、长期三维科研创新体系，短中期内，积极引进优质项目及创新技术，筛选 符合公司发展需要的潜力标的；公司技术中心继续开展新药仿创科研工作，进一步丰富公司细分领域产 品组合，提升公司在该领域竞争力。中长期内，公司继续推进如纳米炭铁等创新技术和产品的开发工 作；推动参股公司康德赛自主研发细胞免疫疗法和其他个性化创新医疗技术等产品，旨在培育核心技术 和长期竞争力。 公司通过研发、产品与渠道拓展的协同优势，积极适应新常态新趋势。报告期内，克林霉素磷酸酯注射 液、盐酸纳洛酮注射液、注射用尼可地尔、阿奇霉素颗粒剂、注射用吗替麦考酚酯、酮咯酸氨丁三醇注 射液等品种取得批件或补充申请批件、通过一致性评价。艾司奥美拉唑镁肠溶胶囊、替米沙坦片、注射 用艾司奥美拉唑 ...

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].